| Cat. No. |
Product Name |
Information |
| PC-22378 |
TYK2 inhibitor X
TYK2 inhibitor
|
TYK2 inhibitor X is a potent, selective TYK2 inhibitor. |
| PC-21236 |
ABBV-712
TYK2-JH2 inhibitor
|
ABBV-712 is a potent, selective inhibitor of tyrosine kinase 2 (TYK2) with EC50 of 0.01 uM, binds and stabilizes the pseudokinase (JH2) domain of TYK2. |
| PC-20516 |
TAK-279
TYK2 inhibitor
|
NDI-034858 (Zasocitinib, TAK-279) is a potent, selective and allosteric TYK2 inhibitor, targets TYK2 JH2 domain with binding KD of 3.8 pM. |
| PC-20143 |
CEE321
pan JAK inhibitor
|
CEE321 (CEE-321) is a potent, selective pan-JAK inhibitor with IC50 of 50, 48, 59 and 48 nM for JAK1, JAK2, JAK3 and TYK2, respectively. |
| PC-49651 |
CPL409116
JAK/ROCK inhibitor
|
CPL409116 (CPL 409116) is a potent, competitive, dual JAK and ROCK inhibitor with IC50 of 0.95/5.36//0.87/110.6/106.7 nM for JAK1/JAK2/JAK3/ROCK1/ROCK2, respectively. |
| PC-49343 |
VVD-118313
JAK1 inhibitor
|
VVD-118313 (VVD118313) is a potent, selective and allosteric inhibitor of the non-catalytic pseudokinase domain of JAK1 (C817), blocks JAK1-dependent trans-phosphorylation and cytokine signaling. |
| PC-49307 |
AZD0449
JAK1 inhibitor
|
AZD0449 (AZD-0449) is a potent and highly selective JAK1 inhibitor with IC50 of 2.4 nM, displays >50-fold selectivity over TYK2 and JAK2, and no inhibition against JAK3. |
| PC-49274 |
Z583
JAK3 inhibitor
|
Z583 is a potent, highly selective JAK3 inhibitor with IC50 of 0.1 nM, 4500-fold selectivity over other JAK subtypes. |
| PC-49112 |
TYK2-JH1 inhibitor 30
TYK2-JH1 inhibitor
|
TYK2-JH1 inhibitor 30 is a potent and selective TYK2-JH1 inhibitor, shows excellent selectivity, pharmacokinetic properties, and in vivo efficacy in a mouse psoriasis model. |
| PC-38399 |
Ilunocitinib
JAK inhibitor
|
Ilunocitinib (LY-3411067) is a potent, small molecule JAK inhibitor. |
| PC-38381 |
Nezulcitinib
pan JAK inhibitor
|
Nezulcitinib (TD-0903) is a inhaled lung-selective pan-JAK inhibitor, targets all JAK isoforms (JAK1, JAK2, JAK3, TYK2), Nezulcitinib is under development for treatment of acute lung injury associated with COVID-19. |
| PC-73438 |
Povorcitinib
JAK1 inhibitor
|
Povorcitinib (INCB054707) is a potent, selective and oral JAK1 inhibitor with IC50 of 8.9 nM, 52-fold selective over JAK2 (IC50=463 nM). |
